Antidote kits, such as antidote treatment, nerve agent autoinjector (ATNAA) and convulsant antidote for nerve agent (CANA), treat symptoms of which type of chemical warfare agent exposure?

• A. Nerve agents.
• B. Vesicants.
• C. Cyanogens.
• D. Incapacitating agents.

Answer: (A)

These antidote kits are designed for nerve agent exposure. Nerve agents inhibit the enzyme acetylcholinesterase, leading to a surge of acetylcholine at muscarinic and nicotinic receptors. That causes a cholinergic crisis with symptoms such as runny secretions, bronchoconstriction, slowed heart rate, pinpoint pupils, muscle fasciculations, and can progress to seizures. The kits pair atropine, which blocks muscarinic effects, with pralidoxime, which can reactivate acetylcholinesterase, and CANA adds a seizure-control component. This combination specifically targets the physiology of nerve agent exposure, not other agent types. Vesicants cause blisters, cyanogens require different cyanide antidotes, and incapacitating agents are managed with other approaches, so they aren’t addressed by these nerve-agent–focused antidotes.